Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Daniel Barocas MD, MPH, FACS

Daniel A. Barocas MD, MPH, FACS

Associate Professor of Urologic Surgery, Center for Surgical Quality and Outcomes Research, Vanderbilt University Medical Center, Nashville, Tennessee

Dr. Barocas received his medical degree at the Johns Hopkins University School of Medicine and went on to complete a residency in urology at the New York Presbyterian Hospital-Weill Cornell Medical Center. He then came to Vanderbilt University Medical Center, where he completed a 2-year fellowship in urologic oncology and a master of public health degree. He has remained at Vanderbilt on faculty since completing fellowship.

Dr. Barocas’ clinical interest is the surgical treatment of genitourinary cancers. He is experienced in open and laparoscopic surgery and is a leader in robotic surgery for genitourinary cancers. Dr. Barocas is a strong patient advocate who partners with patients and families to treat the cancer while preserving quality of life. His research interests include: 1) identifying and ameliorating inappropriate variation in the quality care for genitourinary cancers, such as race- and gender-based variation; 2) quality improvement and patient safety; 3) comparative effectiveness of treatments for urologic cancers. Dr. Barocas’ research efforts are funded by Federal agencies, including National Cancer Institute, the Agency for Healthcare Research and Quality, and the Patient-Centered Outcomes Research Institute. He has authored more than 70 peer-reviewed articles in journals including Journal of Urology, Journal of the American College of Surgeons, and Cancer.

Dr. Barocas serves in a number of leadership positions in academic urology. He was a committee member on the American Urological Association (AUA) guidelines panel for the development of standards for evaluating patients with suspected bladder cancer, and he is a current member of the prostate cancer early detection guidelines panel for the National Comprehensive Cancer Network (NCCN). He also chairs a panel to develop quality measures for treatment of urologic cancers for the Commission on Cancer, in conjunction with the AUA, Society for Urologic Oncology, and the American College of Surgeons (ACS). Dr. Barocas is a frequent invited speaker and lecturer on topics related to his work in urologic oncology, including speakerships at the AUA and ACS annual meetings. He is an Assistant Editor for the Journal of urology, and reviews articles for publications such as Medical Care, JAMA Surgery, and the Journal of Clinical Oncology.

Recent Contributions to PracticeUpdate:

  1. A Risk-Stratified Approach to Active Surveillance in Prostate Cancer
  2. MR-Fusion Targeted Prostate Biopsy in Biopsy-Naive Men
  3. Baseline Perineural Invasion and Shorter Time to Progression in Prostate Cancer Patients Under Active Surveillance
  4. Reduction in Admissions With Prophylactic Intramuscular Ceftriaxone Before Transrectal Ultrasonography-Guided Prostate Biopsies
  5. MY APPROACH to Rising PSA After Negative Biopsy
  6. Sequential BCG and Electromotive Mitomycin for Bladder Cancer
  7. A Single Dose of 240 mg Gentamicin During Transrectal Prostate Biopsy Significantly Reduces Septic Complications

Recently Updated